Analyzing the Results of the Treating to New Targets Study
Authors: Vera Bittner, David Herrington, Nanette Wenger
Journal: Annals of Internal Medicine (2008)

Letters19 February 2008Analyzing the Results of the Treating to New Targets StudyVera Bittner, MD, David Herrington, MD, and Nanette Wenger, MDVera Bittner, MDFrom University of Alabama at Birmingham, Birmingham, AL 35294; Wake Forest University School of Medicine, Winston-Salem, NC 27157; and Emory University School of Medicine, Atlanta, GA 30303.Search for more papers by this author, David Herrington, MDFrom University of Alabama at Birmingham, Birmingham, AL 35294; Wake Forest University School of Medicine, Winston-Salem, NC 27157; and Emory University School of Medicine, Atlanta, GA 30303.Search for more papers by this author, and Nanette Wenger, MDFrom University of Alabama at Birmingham, Birmingham, AL 35294; Wake Forest University School of Medicine, Winston-Salem, NC 27157; and Emory University School of Medicine, Atlanta, GA 30303.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-148-4-200802190-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Alter, Dr. Mascitelli and Mr. Vos, and Dr. Goldstein for their careful reviews of our paper. Treatment effect was qualitatively similar in participants age 35 to 64 years and age 65 to 75 years, providing some reassurance that age does not importantly modify treatment effect. Because treatment duration was 4.9 years, some follow-up is derived from participants older than 75 years. Nonetheless, we agree that the TNT study results do not provide definitive efficacy or safety information for the 5% of the U.S. population older than 75 years. A manuscript comparing outcomes by sex is ...References1. Wenger NK, Lewis SJ, Welty FK, Herrington DM, Bittner V. Beneficial effects of aggressive LDL cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart. [Forthcoming]. Google Scholar2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. [PMID: 15755765] CrossrefMedlineGoogle Scholar3. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-30. [PMID: 12457784] CrossrefMedlineGoogle Scholar4. LaRosa JC, Grundy SM, Kastelein JJP, Kostis JB, Greten H; for the Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets (TNT) study. Am J Cardiol. 2007;100:747-752. [PMID: 17719314] CrossrefMedlineGoogle Scholar5. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45. [PMID: 18174034] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Alabama at Birmingham, Birmingham, AL 35294; Wake Forest University School of Medicine, Winston-Salem, NC 27157; and Emory University School of Medicine, Atlanta, GA 30303.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOutcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease Nanette K. Wenger , Sandra J. Lewis , David M. Herrington , Vera Bittner , Francine K. Welty , and Analyzing the Results of the Treating to New Targets Study Robert A. Alter Analyzing the Results of the Treating to New Targets Study Luca Mascitelli and Eddie Vos Analyzing the Results of the Treating to New Targets Study Mark R. Goldstein Metrics 19 February 2008Volume 148, Issue 4Page: 322-323KeywordsCholesterolCoronary heart diseaseMyocardial infarctionQuality of lifeSafety studiesSpecificityStatins ePublished: 19 February 2008 Issue Published: 19 February 2008 Copyright & PermissionsCopyright © 2008 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...